GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » LT-Debt-to-Total-Asset

OASMY (Vivesto AB) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vivesto AB's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Vivesto AB's long-term debt to total assets ratio declined from Sep. 2023 (0.01) to Sep. 2024 (0.00). It may suggest that Vivesto AB is progressively becoming less dependent on debt to grow their business.


Vivesto AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Vivesto AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB LT-Debt-to-Total-Asset Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.02 - -

Vivesto AB Quarterly Data
Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vivesto AB LT-Debt-to-Total-Asset Calculation

Vivesto AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/21.513
=

Vivesto AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0/18.04
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OTCPK:OASMY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Vivesto AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Vivesto AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB Headlines

From GuruFocus

Oasmia Pharmaceutical AB (publ) - Special Call Transcript

By GuruFocus Research 03-06-2024

Q4 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q2 2022 Vivesto AB Earnings Call Transcript

By GuruFocus Research 03-06-2024